Peter Borchmann^1*, Andreas Engert², Annette Pluetschow^2*, Michael Fuchs^2*, Jana Markova^3*, Andreas Lohri⁴, Zdenek Kral^5*, Richard Greil^6*, Max Topp^7*, Matthias Villalobos^8*, Jose Zijlstra, MD^9*, Martin Soekler^10*, Harald Stein^11*, Hans Theodor Eich^12*, Rolf Peter Mueller^13* and Volker Diehl¹⁴

¹First Department of Internal Medicine, University of Cologne, Cologne, Germany
²First department of Internal Medicine / German Hodgkin Study Group (GHSG), University of Cologne, Cologne, Germany
³Hematologia, Fakultni Nemocnice Kralovske Vinohrady, Prague, Czech Republic
⁴Dept. of Oncology/Hematology, Medical University Clinic, Liestal, Switzerland
⁵Department of Internal Medicine and Hematology, University Hospitel of Brno, Brno, Czech Republic
⁶Third Department of Internal Medicine, University of Salzburg, Salzburg, Austria
⁷Department of Hematology and Oncology, University of Wuerzburg, Wuerzburg, Germany
⁸Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany
⁹Hematology, VU University Medical Centre Amsterdam, Amsterdam, Netherlands
¹⁰Hematology and Oncology, University of Tuebingen, Tuebingen, Germany
¹¹Institute of Pathology, University Hospitel Benjamin Franklin Berlin, Berlin, Germany
¹²Department of Radiotherapy, University of Cologne, Cologne/Germany, Germany
¹³Department of Radiotherapy, University of Cologne, Cologne, Germany
¹⁴First department of Internal Medicine / German Hodgkin Study Group (GHSG), University of Cologne, Cologne/Germany, Germany

Peter W.M. Johnson, MD, FRCP¹, Matthew R Sydes^2*, John Radford, MD, FRCP^3*, Michael Cullen, MD, FRCP^4*, Sally Stenning^2* and Barry Hancock, MD, FRCP^5*

¹Cancer Research UK Clinical Centre, University of Southampton, Southampton, United Kingdom
²MRC Cancer Trials Unit, London, United Kingdom
³Christie Hospital and The University of Manchester, Manchester, United Kingdom
⁴University Hospitals, Department of Medical Oncology, Birmingham, United Kingdom
⁵Weston Park Hospital, Department of Clinical Oncology, Sheffield, United Kingdom

John Radford^1*, Michael O'Doherty^2*, Sally Barrington^2*, Wendi Qian^3*, Philippa Patrick^4*, Stewart Coltart^5*, Dominic Culligan⁶, Jennie Wimperis^7*, Eric Bessell^8*, David Linch^9*, Peter Johnson¹⁰, David Cunningham^11*, T. Andrew Lister¹², Peter Hoskin^13*, Ruth Pettengell^14*, Barry Hancock^15* and Timothy Illidge¹

¹Christie Hospital and The University of Manchester, Manchester, United Kingdom
²PET Imaging Centre, St Thomas' Hospital, London, United Kingdom
³MRC Cancer Trials Unit, London, United Kingdom
⁴Cancer Research UK and University College London Clinical Trials Centre, London, United Kingdom
⁵Kent and Canterbury Hospital, Canterbury, United Kingdom
⁶Aberdeen Royal Infirmary, Aberdeen, United Kingdom
⁷Norfolk and Norwich University Hospital, Norwich, United Kingdom
⁸Nottingham City Hospital, Nottingham, United Kingdom
⁹University College London, London, United Kingdom
¹⁰Cancer Research UK Clinical Centre, University of Southampton, Southampton, United Kingdom
¹¹Royal Marsden Hospital, London, United Kingdom
¹²Centre for Medical Oncology, Barts and the London School of Medicine and Dentistry, London, United Kingdom
¹³Mount Vernon Hospital, Northwood, United Kingdom
¹⁴St Georges University of London, London, United Kingdom
¹⁵Weston Park Hospital, Sheffield, United Kingdom

Peter W.M. Johnson, MD, FRCP¹, Alan Horwich, PhD, FRCR, MRCP^2*, Andrew Jack, MD, FRCPath^3*, Graham Mead, DM, FRCP^1*, Barry Hancock, MD, FRCP^4*, Paul Smith^5*, Wendi Qian^6*, Philippa Patrick, PhD^5*, Andrew Pettitt^7*, David Cunningham^8* and Peter Hoskin, MD, FRCR^9*

¹Cancer Research UK Clinical Centre, University of Southampton, Southampton, United Kingdom
²Department of Radiotherapy, Institute of Cancer Research and Royal Marsden Hosp, London, United Kingdom
³St James's Institute of Oncology, HMDS, Leeds, United Kingdom
⁴Weston Park Hospital, Department of Clinical Oncology, Sheffield, United Kingdom
⁵Lymphoma Trials Office, CR UK UCL Cancer Trials Office, London, United Kingdom
⁶MRC Cancer Trials Unit, London, United Kingdom
⁷University of Liverpool, Liverpool, United Kingdom
⁸Royal Marsden Hospital, London, United Kingdom
⁹Mount Vernon Cancer Centre, Department of Clinical Oncology, London, United Kingdom

Amanda Cashen, M.D., Farrokh Dehdashti, M.D.^*, Jingqin Luo, Ph.D.^* and Nancy L. Bartlett, MD

Washington University School of Medicine, Saint Louis, MO

Sandra J. Horning, MD¹, Malik E. Juweid, MD^2*, Heiko Schoder^3*, Gregory Wiseman, MD^4*, Alex McMillan, Ph.D.^5*, Lode J. Swinnen, MBChB⁶, Ranjana Advani, MD¹, Randy D. Gascoyne, MD⁷ and Andrew Quon^8*

¹Stanford University, Stanford, CA
²Dept. of Radiology/Nuclear Med., Univ. of Iowa College of Med., Iowa City, IA
³Radiology/Nuclear Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
⁴Mayo Clinic, Rochester, MN
⁵Health Research and Policy, Stanford University, Stanford, CA
⁶Div. of Hem. Malignancy, Johns Hopkins Cancer Center, Baltimore, MD
⁷British Columbia Cancer Agency, Vancouver, BC, Canada
⁸Radiology/Nuclear Medicine, Stanford University, Stanford, CA